Canadian Journal of Emergency Medicine (2025) 27:678–685
https://doi.org/10.1007/s43678-025-00961-y

CAEP POSITION STATEMENT & GUIDELINES

CAEP Acute Heart Failure Best Practices Checklist

Ian G. Stiell[1] · Aws Almufleh[10] · Patrick M. Archambault[3] · Marc Bains[26] · Sophie Boisvert[16] · Bjug Borgundvaag[20] · Darshan H. Brahmbhatt[24] · Nadia Bouabdallaoui[21] · Christian Chabot[27] · Heather D. Clark[28] · Alexis Cournoyer[4] · Kerstin de Wit[5,6] · Debra Eagles[1] · Ian D. Graham[8,9] · Caroline McGuinty[18] · Andrew D. McRae[7] · Robert J. Miller[14] · Judy Morris[4] · Stuart G. Nicholls[8] · Robert Ohle[17] · Jeffrey J. Perry[1] · Brian H. Rowe[11] · Rupinder Sahsi[23] · Frank Scheuermeyer[15] · Guillaume St-Pierre[25] · Brian Steinhart[22] · Troy Tebbenham[12] · Suneel Upadhye[19] · Alain Vadeboncoeur[2] · Krishan Yadav[1] · Justin W. Yan[13] · Amelia Yip[23]

Received: 30 May 2025 / Accepted: 12 June 2025 / Published online: 2 September 2025
© The Author(s) 2025

A. Assessment

1. What is acute heart failure (AHF)?

- **Heart failure (HF)** is a syndrome that results from the structural or functional impairment of ventricular filling or ejection of blood.
- **Cardinal manifestations** include dyspnea, fatigue, pulmonary and/or splanchnic congestion, and peripheral edema.
- **Acute heart failure** is a common condition that frequently results in poor outcomes or death [1, 2].
  - patients typically present to the emergency department (ED) with **increased shortness of breath**.
  - may be the first episode of HF (**new onset**) or, more frequently, be due to acute decompensation of **chronic HF**.
- **Diagnosis** is primarily clinical assisted by selected investigations [3].

Left ventricular ejection fraction (LVEF) *in heart failure is classified as:*

• HF with **preserved** ejection fraction	**(HFpEF)**	LVEF ≥50%
• HF with **mildly reduced** ejection fraction	**(HFmrEF)**	LVEF 41%-49%
• HF with **reduced** ejection fraction	**(HFrEF)**	LVEF ≤40%
• HF with **improved** ejection fraction	**(HFimpEF)**	compared to baseline

2. How does acute heart failure present?

- There are four major clinical presentations with possible overlap:

A. **Acute decompensated heart failure (ADHF)**

- onset of dyspnea ***over days***
- pulmonary congestion, jugular venous distension, peripheral edema
- the most common form, accounting for 50–70% of ED presentations

B. **Acute pulmonary edema** (aka "*flash pulmonary edema*")

- onset of dyspnea ***over hours***
- pulmonary congestion causes dyspnea with orthopnea, tachypnea, and hypoxia

C. **Isolated right ventricular (RV) failure**

- caused by RV dysfunction, severe pulmonary hypertension, or severe tricuspid valve disease
- **symptoms** often nonspecific: exertional dyspnea, fatigue, early satiety, symptoms of right-sided volume overload
- **physical findings** include jugular venous distension, often with a prominent V wave and positive Kussmaul sign, ascites, leg edema
- often poor outcomes

Extended author information available on the last page of the article

SHOUT
SHARE
IT

D. **Cardiogenic shock**

- due to **primary cardiac** dysfunction that results inadequate cardiac output and life-threatening tissue hypoperfusion, which can lead to multiorgan failure and has > 30% mortality
- may be precipitated by acute events (e.g. myocardial infarction (MI), myocarditis) or acute decompensation of chronic left ventricular (LV) dysfunction
- diagnosis is based on evidence of hypoperfusion:

– signs: cold wet extremities, mottling, oliguria, mental confusion, narrow pulse pressure
– blood pressure Is often low (SBP < 90 mmHg) but may be preserved by reflex vasoconstriction
– low urine output
– laboratory: metabolic acidosis with elevated serum lactate, creatinine, and/or liver enzymes

3. Diagnosis of acute heart failure

- **Etiology and precipitating factors** should be considered:

  - non-adherence with diet/sodium/water
  - non-adherence with or recent change in medication; chemotherapeutic agents
  - infections (*pneumonia, influenza, endocarditis, myopericarditis*)
  - arrhythmias (*atrial fibrillation* (*AF), atrial flutter (AFL), bradycardia, ventricular tachycardia*)
  - pulmonary embolism
  - MI, acute coronary syndrome (ACS)
  - hypertensive emergency

TIP: Consider alternative or precipitating diagnoses for acute severe dyspnea:

- *myocardial infarction (MI)*
- *pneumonia*
- *pulmonary embolism*
- *exacerbation of asthma/COPD*
- *pericardial tamponade*
- *pneumothorax*
- *acute valve regurgitation*
- *acute aortic syndrome*
- *arrhythmias: VT, SVT, AF, AFL*

- **History** focuses on:

  - worsening symptoms (*dyspnea, orthopnea, and paroxysmal nocturnal dyspnea*)
  - recent weight gain
  - history of heart failure and echocardiography results
  - history of coronary artery disease
  - medications

- **Clinical exam** focuses on impact of lung congestion:

  - agitation, somnolence, confusion
  - poor perfusion, cyanosis, diaphoresis
  - breathless speech
  - inability to lie supine
  - usually afebrile, tachypnea, low oxygen saturation, tachycardia
  - peripheral/sacral edema
  - jugular venous distension (JVD), hepatojugular reflux (HJR)
  - crackles, wheezing
  - extra heart sounds, murmurs

- **Point-of-care ultrasound** (POCUS) can rapidly assess:

  - lung congestion (*pleural effusion, bilateral B-lines)*
  - qualitative LV function
  - JVD
  - RV filling pressure estimation by measurement of inferior vena cava (IVC)
  - pericardial effusion

- **ECG** helps identify:

  - rhythm abnormalities (*AF/AFL, heart block, bradycardia, and ventricular tachycardia*)
  - acute myocardial ischemia
  - RV, LV, or atrial hypertrophy or strain
  - myopericarditis
  - use 15-lead ECG for posterior ischemia, if shock

- **Investigations** include hematology, chemistry, and troponin.
  – **NT-proBNP** strongly recommended:

    – **< 300 pg/ml**—unlikely AHF
    – **300–900 pg/ml** (*age 50–75*) or **300–1800** (*age > 75*)–consider use of **PRIDE HF Score**
    – **> 900 pg/ml** (*age 50–75*) or > **1800** (*age > 75*)—likely AHF

- **Chest X-ray** for cardiomegaly, lung congestion *(redistribution, Kerley B lines, interstitial fluid),* other conditions.

- **The PRIDE HF Scale** can be helpful when the diagnosis is uncertain: [4]

PRIDE Acute Heart Failure Score[4]

Predictor	Score
Interstitial edema on CXR	2
Orthopnea	2
Lack of fever	2
On loop diuretic	1
Age >75 years	1
Crackles/rales on lung exam	1
Lack of cough	1
Elevated NT-proBNP	4
▪ *> 450 pg/mL if age <50*	
▪ *> 900 pg/mL if age ≥50*	

Likelihood of HF	Total Score
Low	0-5
Intermediate	6-8
High	9-14

B. Treatment

1. Overall approach (see specific conditions below)

- **Treat underlying causes:**
  - infections, arrhythmias, pulmonary embolism, ACS, hypertension.
- **Oxygen** should be used cautiously in patients with normal oxygen saturation because of concerns of increasing systemic vascular resistance and reducing cardiac output.
  - **give oxygen** for patients who are hypoxemic, titrated to an oxygen saturation > 90%.
- **Noninvasive ventilation (NIV)** through BiPAP or CPAP should be considered for patients with a high respiratory rate (> *25 breaths/min*), respiratory fatigue, and persistent hypoxemia despite high-flow oxygen.
  - **routine use** of NIV is not advisable due to risk of worsening right HF, hypercapnia, aspiration, and pneumothorax.
  - NIV may be useful in **hemodialysis patients** with acute HF.
- **Endotracheal intubation** should be used if less invasive modes of oxygen delivery and ventilation support fail.
  - order **blood gases** if ventilatory fatigue a concern.
- **IV diuretics** remain the mainstay of therapy and should be administered as early as possible
  - use **bolus administration** as no advantage to continuous infusion [5].
  - start with an initial **IV dose of furosemide:**
    - if patient already taking diuretics, give **1–2 times the daily oral dose** as the initial IV dose.
    - if patient **not on oral diuretics**, suggest:

- **20 mg furosemide** for eGFR >60
- **40 mg furosemide** for eGFR 30-60
- **60-80 mg furosemide** for eGFR <30

  - assess for **satisfactory diuretic response:**
    - **urine output** > 100–150 mL/h during the first 6 h.
    - **urine sodium content** > 50–70 mEq/L at 2 h.
  - **if insufficient diuretic response:** confirm diagnosis of AHF and then double the IV diuretic dose.
  - **if response remains suboptimal** patient may be in normotensive cardiogenic shock.
- **IV morphine** should not be used as it increases morbidity and mortality.
- **Vasodilators and inotropic agents** should only be used in selected patients (*e.g., pulmonary edema, cardiogenic shock*) as they do not improve outcomes in most patients.
- **Beta-blockers and calcium-channel blockers** should be avoided in management of tachycardia and AF/AFL if LVEF is low or not known.

2. Acute pulmonary edema

- **Three treatments** should be commenced, if indicated, simultaneously:

A. **Oxygen** should be given using NIV or high-flow nasal cannula [6].
B. **IV diuretics** should be administered, as above.
C. **Nitroglycerin** should be given if systolic BP (SBP) ≥ 100 mmHg, to reduce LV afterload.

  - consider immediate **sublingual nitroglycerin spray** (*1–2 sprays at 400 µg/spray*) followed by IV.
  - give **IV nitroglycerin** in an initial dose of 5 to 10 µg/min and increase by 5 to 10 µg/min every 3–5 min as required and tolerated (*dose range 10 to 200 µg/min*).
  - **high-dose nitrates** may be considered if SBP ≥ 160 mmHg: [7, 8]
  - **start at 100 µg/min** and rapidly titrate as tolerated to 200 µg/min (*maximum 400 µg/min*).
  - **decrease dose** as dyspnea and SBP improve.

- **IV nitroprusside** may be used by experienced physicians.

3. Isolated right ventricular failure

- **Rule out** ACS with RV involvement or pulmonary embolism.
- **Diuretics** are the main therapy for venous congestion.
- **Involve cardiology** early if the patient has severe pulmonary hypertension or fails to respond to diuretics.

4. Cardiogenic shock

- **Consult cardiology/critical care urgently.**
- Identify and treat **underlying causes:**
  - if **ACS**, consider percutaneous coronary intervention (PCI).
  - if **tamponade**, consider pericardiocentesis.
  - if **papillary muscle rupture**, consider surgery.
  - **other** (*acute valve regurgitation, pulmonary embolism, infection, myocarditis, arrhythmia).*
- Provide **oxygen** and consider **ventilatory support.**
  - if intubation is needed, choose a **sedative agent** with caution—consider ketamine or etomidate.
  - for ongoing sedation, consider IV midazolam and fentanyl and **avoid propofol.**
- Consider **inotropes/vasopressors** [9]:

- **norepinephrine** is first line: start at 0.05 ug/kg/min and titrate up
- **dobutamine** 2-10 ug/kg/min
- **milrinone** 0.25-0.75 ug/kg/min

- Consider expert consultation for **mechanical circulatory support** (*percutaneous LV assist devices or ECMO).*

C. Disposition and follow-up

1. How to decide if patient can be discharged home

- **Disposition decision** to admit or discharge from the ED is complex.
  - ≥ 50% of ED acute HF patients are admitted in Canada.
- Use **shared decision making** with patient and family.

NYHA

Class	Definition
I	No symptoms
II	Symptoms with ordinary activity
III	Symptoms with less than ordinary activity
IV	Symptoms at rest or with minimal activity

- **Factors to consider:**
  - **clinical classification** NYHA I or II at baseline
  - **not a new diagnosis** of heart failure
  - **response to ED treatment:** good diuresis, improved dyspnea approaching patient's baseline
  - **acceptable vital signs** at rest after treatment: *$SpO_2 > 92\%$, SBP > 100mmHg, HR < 90bpm, RR ≤ 20 breaths per minute*
  - **ability to walk** (or baseline level of mobility) without tachycardia, tachypnea, or hypoxia
  - **ECG** shows no ischemia or ventricular arrhythmia; any atrial arrhythmia has been controlled
  - **creatinine** at baseline after treatment
  - **troponin** not indicative of ACS
  - **no comorbid conditions** that independently require admission (*e.g. syncope, pneumonia*)
  - opportunity to **optimize medications—***see below*
  - availability of **early follow-up** (< 7 days) with clinician
  - **home support** is adequate

2. What is the HEARTRISK6 Scale? [10]

- **The HEARTRISK6 Scale** is a concise and sensitive risk tool comprised of 6 simple variables that estimates the risk of poor outcomes.
- The scale was developed from prospectively collected data from **2,246 Canadian ED patients**.
- Physicians **may consider** incorporating the scale's information when making disposition decisions.
- Medium- and high-risk patients should likely be admitted.

HEARTRISK6 Acute Heart Failure Risk Scale Items	Points
1. Initial Assessment	
a. History of valvular heart disease[1]	1
b. Heart Rate:	
i. HR > 100 bpm to < 120 bpm	2
ii. HR > 120 bpm	3
c. Treated with non-invasive ventilation[2]	2
2. Investigations	
a. Creatinine:	
i. > 150 umol/L to < 300 umol/L	2
ii. > 300 umol/L	3
b. Troponin:	
i. > 3 × or 4 × upper limit of normal	1
ii. > 5 × upper limit of normal	2
(initial or repeat, local hospital assay)	
3. Falls reassessment after ED treatment (2–6 h)	
a. Resting vital signs abnormal *(SpO2 < 90% on RA or usual O2, or HR ≥ 110, or RR ≥ 28)*	1
OR	
b. Unable to start or complete 3-min walk test *(vital signs become abnormal during walk)*[3]	1

[1]Moderate or severe valvular heart disease

[2]BiPAP within one hour of initial assessment

[3]Score if patient SpO2 < 90%, HR ≥ 110, RR ≥ 28 during walk test, or if unable to complete due to fatigue or dyspnea

Heart failure risk categories for short-term serious outcomes		
Total Score	Absolute Risk	Category
0	6.4%	Low
1	8.5%	
2	11.3%	Medium
3	14.9%	
4	19.4%	
5	24.8%	
6	31.2%	High
7	38.3%	
8	48.0%	
9	53.9%	
> 10*	61.6%	

*No patient scored > 11

3. How to optimize discharge medications

- **Diuretics** should be started or increased in patients presenting with volume overload.
  - consider a temporary increase of **2 × current dose** for 5–10 days.
  - a typical starting dose is **furosemide 20 mg** once or twice daily, but should be based on IV diuretic requirements.
  - **electrolytes and creatinine** checked within 7 days.
  - for new prescriptions, provide at least **1 month supply**.
- **Guideline-directed medical therapy (GDMT)** medications should be continued.
- **Other medications** may be prescribed by consultants:
  - **angiotensin-converting enzyme (ACE) Inhibitors /angiotensin-receptor blockers (ARB), or angiotensin neprilysin inhibitors (ARNI)** could be considered in patients with SBP > 100 mmHg, with stable renal function, and in whom follow-up laboratory testing can be arranged.
  - **mineralocorticoid receptor antagonists (MRA)** could be considered in patients with stable renal function and in whom follow-up testing for hyperkalemia can be arranged.
  - in patients on **beta-blockers**, continuation of therapy is safe.
    - decisions **to start or increase** dose should consider the potential benefits and harms.
- **Sodium-glucose cotransporter-2 (SGLT2) inhibitors** may be continued if stable renal function.

4. What is appropriate follow-up?

- Patients discharged home from the ED should **ideally be seen within 7 days** by their primary care practitioner or by a new referral to primary care/internist/cardiologist/HF clinic.
- Provide **written instructions** of diagnosis, results, medications, follow-up.
- Instruct patient to **return to the ED** if symptoms worsen.

Discharge Instructions (see French version in supplement)

You were treated on _____ at the emergency department of _____ Hospital for **acute heart failure**. Acute heart failure results from weakness of the heart muscle and causes shortness of breath due to fluid in the lungs.

The following **medication changes** have been recommended:

_____

Please seek **medical follow-up** within 7 days at _____ (primary care practitioner, internist/cardiologist, hospital clinic).

Please **return to the emergency department** immediately if you become short of breath or develop chest pain.

Other recommendations:

- **Weigh yourself** and measure blood pressure and heart rate daily.
- Adhere to **low salt diet** (sodium <2 gram/day, e.g. 1tsp salt) and **restrict fluids** (< 2 Litres/day.
- Obtain **immunization** for influenza, RSV and pneumonia, if not already done.
- If a smoker, consider a **smoking cessation** program.
- Consider the **HeartLife toolkit** https://heartlife.ca/document/heartlife-toolkit/


CAEP Acute Heart Failure Checklist
Diagnosis of heart failure is primarily clinical
⬆dyspnea / ⬆weight / fatigue / ⬆H2O-Na intake / ⬇compliance
Signs: JVD / Crackles / Wheezing / Peripheral Edema
Perform: ECG / CXR / Electrolytes / Creatinine / Troponins
POCUS : B-lines / Pleural effusion / LV dysfunction
CXR: Kerley B-lines / Congestion / Effusion / ⬆❤
⬆NT-ProBNP
HF unlikely if < 300 pg/ml for all
HF likely if > 300 for < 50 yo
> 900 for 50-75 yo
> 1800 for > 75 yo
PRIDE HF Scale
can be helpful when
the diagnosis is uncertain
Treat any underlying causes
Infections Arrhythmias PE ACS Hypertension
Avoid
IV morphine
B-blockers and Ca-channel blockers
Acute Decompensated HF
IV DIURETICS are mainstay :
IV FUROSEMIDE bolus 20–80 mg
give 1–2 x daily dose
if naive give 20–80 mg per eGFR
satisfactory urine output >100–150 mL/h
if unsatisfactory response, double dose
Give OXYGEN cautiously
titrate to O2 sats >90%
Consider NIV
do not use routinely
Acute Pulmonary Edema
3 treatments simultaneously :
OXYGEN – NIV or high-flow cannula
IV DIURETICS – as in ADHF
NITROGLYCERIN – if SBP >100 mmHg
Consider SL spray 400 µg
IV nitroglycerin initial 5–10 µg/min
– increase by 5–10 µg/min q 3–5 min
– range 10–200 µg/min
Consider high-dose nitrates if SBP ≥160
– start at 100 µg/min
– rapidly titrate as tolerated to 400 µg/min
– decrease as dyspnea and SBP improve
Cardiogenic Shock
Consult cardiology / critical care
Treat underlying causes :
ACS, pericardial tamponade, papillary muscle rupture, other as above
OXYGEN consider NIV-intubation, safely sedate
INOTROPES / VASOPRESSORS :
1st NOREPINEPHRINE 0.05 µg/kg/min + titrate up
add DOBUTAMINE 2–10 µg/kg/min
or MILRINONE 0.25–0.75 µg/kg/min
Consider mechanical support
expert consultation
Discharge shared decision-making
up to 6-12h after arrival for stable patients
Admit
INTUBATE if O2 and NIV fail
Consider discharge if
Improving symptoms
SaO2 ≥ 92%
Acceptable vitals signs
Diuresis > 150 mL/h
Able to walk or back to baseline
Stable housing with available social support
HEARTRISK6 score 0-1
Prescribe
Double furosemide dose for 5-10 days
Limit salt and water
Adjust other HF meds prn
Organize follow-up
Within 7 days by PCP or new referral
Provide written instructions
Suggest ED return if symptoms worsen

Figure Overall management scheme

Advisory Committee Members (31)

Academic Emergency Medicine	**Institution**
Ian Stiell (Chair)	Ottawa Hospital, ON
Patrick Archambault	Hôtel-Dieu de Lévis, Lévis, QC
Bjug Borgundvaag	Sinai Health, Toronto, ON
Alexis Cournoyer	Hôpital du Sacré-Cœur, Montréal, QC
Kerstin de Wit	Kingston HSC, ON
Debra Eagles	Ottawa Hospital, ON
Andrew McRae	Foothills Hospital, Calgary, AB
Judy Morris	Hôpital du Sacré-Cœur, Montréal, QC
Robert Ohle	Health Sciences North, Sudbury, ON
Jeff Perry	Ottawa Hospital, ON
Brian H. Rowe	U of Alberta Hospital, Edmonton, AB
Frank Scheuermeyer	St Pauls Hospital, Vancouver, BC
Brian Steinhart	Unity Health, Toronto, ON
Alain Vadeboncoeur	Montreal Heart Institute, QC
Krishan Yadav	Ottawa Hospital, ON
Justin Yan	London HSC, ON
Community Emergency Medicine	
Rupinder Sahsi	Grand River Hospital, Kitchener, ON
Troy Tebbenham	Peterborough Regional Health Center, ON
Suneel Upadhye	Niagara Falls, ON
Cardiology/Internal Medicine	
Aws Almufleh	Kingston Health Science Centre, ON
Darshan Brahmbhatt	Sinai Health, Toronto, ON
Nadia Bouabdallaoui	Montreal Heart Institute, QC
Heather Clark	Ottawa Hospital, ON
Caroline McGuinty	Ottawa Heart Institute, ON
Robert J. Miller	Libin Cardiovascular Institute, Calgary, AB
Guillaume St-Pierre	Hôtel-Dieu de Lévis, Lévis, QC
Amelia Yip	St Mary's Hospital, Kitchener, ON
Methodology (PhD)	
Ian D. Graham	Ottawa Hospital Research Institute, ON
Stuart Nicholls	Ottawa Hospital Research Institute, ON
Sophie Boisvert	Université du Québec, Lévis, QC
Patient Partners	
Marc Bains (Patient)	HeartLife Foundation
Christian Chabot (Patient)	Quebec City, QC

Background and methods

We created the *CAEP Acute Heart Failure Best Practices Checklist* to assist emergency physicians in Canada and elsewhere manage patients who present to the emergency department (ED) with acute heart failure. While there are several excellent cardiology society heart failure guidelines, there is nothing specific for ED management. The checklist attempts to fill that gap and focuses on patients presenting with one of four heart failure syndromes, acute decompensated heart failure, acute pulmonary edema, isolated right ventricular failure, and cardiogenic shock. There are detailed sections on diagnosis, treatment, disposition and follow-up.

The methodology and the format are similar to that of the *2021 CAEP Acute Atrial Fibrillation/Flutter Best Practices Checklist*. [11] We chose to adapt, for use by emergency physicians, existing high-quality clinical practice guidelines previously developed by the Canadian Cardiovascular Society (CCS) [1, 12]. These guidelines were developed and revised using a rigorous process that is based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system of evaluation [13]. With the assistance of our PhD methodologist (IDG), we used the recently developed Canadian CAN-IMPLEMENT© process adapted from the ADAPTE Collaboration [14, 15]. We also reviewed heart failure guidelines from the European Society of Cardiology and the American College of Cardiology/American Heart Association/Heart Failure Society of America [2, 9]. We created an Advisory Committee consisting of 16 academic emergency physicians, three community emergency physicians, seven cardiologists, one general internist, three PhD methodologists, and two patient partners. The checklist was prepared and revised through a process of iterative feedback and discussions on all issues by all panel members. There were nine rounds of revisions until consensus was achieved. We then circulated the draft checklist for comment to approximately 500 Canadian emergency medicine and cardiology colleagues. Finally, the CAEP Standards Committee posted the Checklist online for all CAEP members to provide feedback. Only minor changes resulted from this feedback. The document has been approved by the CAEP Board.

While the panelists did offer the option of high dose nitrates for acute pulmonary edema, they chose not to use the term "SCAPE" (sympathetic crashing acute pulmonary edema) because it is not widely used and because the supporting evidence is weak.

Our hope is that the *CAEP Acute Heart Failure Best Practices Checklist* will standardize and improve care of acute heart failure in large and small EDs alike.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s43678-025-00961-y.

Acknowledgements We thank the hundreds of Canadian emergency physicians and cardiologists who reviewed the draft guidelines and who provided very helpful feedback. We thank Ottawa Hospital Research Institute Emergency Research staff for their assistance: Angela Marcantonio, Catherine Clement, Carolyne Kennedy, Isabella Welch.

Funding Funding for this guideline was provided by The Ottawa Hospital Academic Medical Organization (TOHAMO).

Declarations

Conflict of interest The authors declare that there are no competing interests.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Can J Cardiol. 2017;33(11):1342–433. https://doi.org/10.1016/j.cjca.2017.08.022. (**published online first: 2017/11/08**).
2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab368. (**published online first: 2021/08/28**).
3. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352–80. https://doi.org/10.1002/ejhf.2115. (**published online first: 20210303**).
4. Baggish AL, Siebert U, Lainchbury JG, et al. A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J. 2006;151(1):48–54. https://doi.org/10.1016/j.ahj.2005.02.031.
5. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805. https://doi.org/10.1056/NEJMoa1005419.
6. Yan L, Lu Y, Deng M, et al. Efficacy of high-flow nasal cannula in patients with acute heart failure: a systematic review and meta-analysis. BMC Pulm Med. 2023;23(1):476. https://doi.org/10.1186/s12890-023-02782-0. (**published online first: 20231128**).
7. Long B, Brady WJ, Gottlieb M. Emergency medicine updates: Sympathetic crashing acute pulmonary edema. Am J Emerg Med. 2025;90:35–40. https://doi.org/10.1016/j.ajem.2024.12.061. (**published online first: 20250105**).
8. Siddiqua N, Mathew R, Sahu AK, et al. High-dose versus low-dose intravenous nitroglycerine for sympathetic crashing acute pulmonary edema: a randomised controlled trial. Emerg Med J. 2024;41(2):96–102. https://doi.org/10.1136/emermed-2023-213285. (**published online first: 20240122**).
9. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263–421. https://doi.org/10.1016/j.jacc.2021.12.012. (**published online first: 2022/04/06**).
10. Stiell IG, Perry JJ, Eagles D, et al. The HEARTRISK6 Scale: predicting short-term serious outcomes in emergency department acute heart failure patients. JACC Adv. 2024;3(7): 100988. https://doi.org/10.1016/j.jacadv.2024.100988. (**published online first: 20240524**).
11. Stiell IG, de Wit K, Scheuermeyer FX, et al. CAEP Acute Atrial Fibrillation/Flutter Best Practices Checklist. CJEM. 2021. https://

doi.org/10.1007/s43678-021-00167-y. (**published online first: 2021/08/13**).
12. Ducharme A, Zieroth S, Ahooja V, et al. Canadian Cardiovascular Society-Canadian Heart Failure Society focused clinical practice update of patients with differing heart failure phenotypes. Can J Cardiol. 2023;39(8):1030–40. https://doi.org/10.1016/j.cjca.2023.04.022. (**published online first: 20230509**).
13. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
14. The ADAPTE Collaboration (2009) The ADAPTE Process: Resource Toolkit for Guideline. Version 2.0. Available from http://www.g-i-n.net
15. Harrison MB, van den Hoek J, Graham ID. CAN-IMPLEMENT: planning for best-practice implementation. Philadelphia, PA, 2014:1-148 Wolters Kluwer

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Ian G. Stiell[1] · Aws Almufleh[10] · Patrick M. Archambault[3] · Marc Bains[26] · Sophie Boisvert[16] · Bjug Borgundvaag[20] · Darshan H. Brahmbhatt[24] · Nadia Bouabdallaoui[21] · Christian Chabot[27] · Heather D. Clark[28] · Alexis Cournoyer[4] · Kerstin de Wit[5,6] · Debra Eagles[1] · Ian D. Graham[8,9] · Caroline McGuinty[18] · Andrew D. McRae[7] · Robert J. Miller[14] · Judy Morris[4] · Stuart G. Nicholls[8] · Robert Ohle[17] · Jeffrey J. Perry[1] · Brian H. Rowe[11] · Rupinder Sahsi[23] · Frank Scheuermeyer[15] · Guillaume St-Pierre[25] · Brian Steinhart[22] · Troy Tebbenham[12] · Suneel Upadhye[19] · Alain Vadeboncoeur[2] · Krishan Yadav[1] · Justin W. Yan[13] · Amelia Yip[23]

✉ Ian G. Stiell
istiell@ohri.ca

1 Department of Emergency Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada

2 Institut de Cardiologie de Montréal, Université de Montréal, Montréal, QC, Canada

3 Département de Médecine Familiale et de Médicine d'urgence et Département d'anesthésiologie et de Soins Intensifs, Centre de Recherche du Centre Intégré de Santé et de Services Sociaux de Chaudière-Appalaches, Université Laval, Québec City, QC, Canada

4 Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) du Nord-de-l'Île de-Montréal, Sacré-Coeur Hospital, Département de Médecine de Famille et Médecine d'urgence, Montréal, QC, Canada

5 Department of Emergency Medicine, Queen's University, Kingston, ON, Canada

6 Division of Emergency Medicine, Department of Medicine, McMaster University, Hamilton, ON, Canada

7 Department of Emergency Medicine, and Community Health Sciences, University of Calgary, Calgary, AB, Canada

8 Methodological and Implementation Research (MIR), Ottawa Hospital Research Institute, Ottawa, ON, Canada

9 School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada

10 Division of Cardiology, Department of Medicine, Queen's University, Kingston, ON, Canada

11 Department of Emergency Medicine and School of Public Health, College of Health Sciences, University of Alberta, Edmonton, AB, Canada

12 Peterborough Regional Health Centre, Peterborough, ON, Canada

13 Division of Emergency Medicine, Department of Medicine, Western University, London, ON, Canada

14 Department of Cardiac Sciences, University of Calgary, Calgary, AB, Canada

15 Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada

16 Université du Québec à Rimouski (UQAR), Centre de Recherche du Centre Intégré de Santé et de Services Sociaux de Chaudière-Appalaches, Lévis, QC, Canada

17 Clinical Sciences Division, Northern Ontario School of Medicine, Health Sciences North Research Institute, Sudbury, ON, Canada

18 Division of Cardiology, Ottawa Heart Institute, University of Ottawa, Ottawa, ON, Canada

19 Division of Emergency Medicine, McMaster University, Hamilton, ON, Canada

20 Schwartz/Reisman Emergency Medicine Institute, Sinai Health System, University of Toronto, Toronto, Canada

21 Centre Hospitalier de l'Université de Montréal and Université de Montréal, Montréal, QC, Canada

22 Division of Emergency Medicine, Unity Health, University of Toronto, Toronto, ON, Canada

23 Waterloo Regional Health Network, McMaster University, Kitchener, ON, Canada

24 Division of Cardiology, Sinai Health System, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ON, Canada

25 CISSS de Chaudière-Appalaches, Hôtel-Dieu de Lévis, Université Laval, Québec City, QC, Canada

26 HeartLife Foundations, Ottawa, ON, Canada

27 Quebec City, QC, Canada

28 Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada